Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management

Oncologist

Volumn 10, Issue 1, 2005, Pages 63-71

  Couture, F ^a,b   Turner, A R ^c   Melosky, B ^d   Xiu, L ^e   Plante, R K ^f   Lau, C Y ^f   Quirt, I ^g  

^a Hotel Dieu de Levis Hospital   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f Janssen Ortho Inc   (Canada)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Anemia; Epoetin alfa; Quality of life; Transfusion reduction

Indexed keywords

CISPLATIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CANCER; CANCER RISK; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; META ANALYSIS; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK FACTORS;

EID: 12844275064     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-1-63     Document Type: Article

References (44)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep 2004;6:297-304.
3. Ludwig H, Birgegard G, Barrett-Lee P et al. Prevalence and management of anemia in patients with hematologic malignancies and solid tumours: results from the European Cancer Anaemia Survey (ECAS). Blood 2002;100:234a-235a.
4. Knight K, Wade, S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(suppl 7A):11S-26S.
5. Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(suppl 2):4-12.
6. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The Oncologist 2000;5:353-360.
7. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998;18:156-169.
8. Shao W, Edelman LS, Sullivan DJ et al. Long-term cytokine alterations following allogeneic blood transfusions. J Investig Med 1998;4:161-167.
9. Brand A. Immunological aspects of blood transfusions. Transpl Immunol 2002;10:183-190.
10. Tartter PI. Immunologic effects of blood transfusion. Immunol Invest 1995;24:277-288.
11. Blajchman MA. Immunomodulation and blood transfusion. Am J Ther 2002;9:389-395.
12. Spirtos NM, Westby CM, Averette HE et al. Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am J Clin Oncol 2002;25:398-403.
13. Fergusson D, Khanna MP, Tinmouth A et al. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials, Can J Anaesth 2004;51:417-425.
14. Canadian Blood Services 2004 (http://www.bloodservices.ca/CentreApps/ Internet/UW_V502_MainEngine.nsf/resources/BloodBeat-2002-02/$file/E_BB04. pdf).
15. American Red Cross 2004 (http://www.redcross.org/news/archives/2000/7- 12a-00.html).
16. Abels RI, Larholt KM, Krantz KD et al. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. In: Murphy MJ Jr, ed. Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Proceedings of the Beijing Symposium. Ohio: Alpha Med Press, 1991:121-141
17. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-179.
18. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
19. Ferrario E, Ferrari L, Bidoli P et al., Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30:563-575.
20. Chang J, Couture F, Young S et al. Once weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy J Clin Oncol 2004 (epub ahead of print).
21. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
22. Demetri G, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
23. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
24. Quirt I, Robeson C, Lau CY et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-4134.
25. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
26. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-4453.
27. Cazzola M, Ponchio L, Pedrotti C et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996;81:434-441.
28. Österborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996;87:2675-2682.
29. Stasi R, Brunetti M, Bussa S et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997;3:733-739.
30. Littlewood TJ, Zagari M, Pallister C et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. The Oncologist 2003;8:99-107.
31. Savonije JH, van Groeningen CJ, van Bochove A et al. Early intervention with epoetin alfa during platinum-based chemotherapy. Proc Am Soc Clin Oncol 2004;22:8111.
32. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992:87(suppl 1):4-11.
33. Abels RI. Recombinant human erythropoietin therapy for the anemia of cancer. Leuk Lymphoma 1992;7:94-96.
34. Abels, R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A(suppl 2):S2-S8.
35. Abels RI, Larholt KM, Krantz KD et al. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. The Oncologist 1996;1:140-150.
36. An integrated statistical analysis of factors associated with a positive predictive response in EPREX-treated cancer patients. Johnson & Johnson Pharmaceutical Research and Development. Document EDMS-USRA-5186082:2.0, 2000.
37. SAS Institute, SAS/STAT Software: Changes and Enhancements Through Release 6.11, SAS Institute, Cary, NC: 1996.
38. Stone M. Cross-validatory choice and assessment of statistical predictions. J R Stat Soc 1974;Series B 36:111-147.
39. Stone M. Asymptotics for and against cross-validation. Biometrika 1977;64:29-35.
40. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
41. Österborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998;15(suppl 1):S47-S49.
42. Clark O, Adams JR, Bennett CL et al. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002;2:23.
43. Henry DH. The evolving role of epoetin alfa in cancer therapy. The Oncologist 2004;9:97-107.
44. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-1221.